About Forendo Pharma
Forendo Pharma is a drug development company aiming for novel treatment solutions for endometriosis patients, by using tissue-specific hormone inhibitors, to rebalance local estrogen metabolism.
The key differentiator of the company’s lead HSD17B1 inhibitor compared to other drug treatments is the ability to act locally without impacting the systemic estrogen levels. The company was founded in 2013 by leading academic endocrinology professionals and Finnish drug development pioneers. Forendo is supported by strong investors with broad international contacts: Novo Seeds, Karolinska Development, Novartis Venture Fund, Merck Ventures and Innovestor. T
he company pipeline includes HSD17B1 inhibitor (preclinical) for the treatment of endometriosis; Dual HSD inhibitor (discovery) for the treatment of endometriosis, with potential for other endocrinological diseases; Fispemifene (phase 2), novel SERM for the treatment of male urological conditions.
State of Ownership
Sales Account Executive, Springer Nature